|
1
|
Jemal A, Siegel R, Ward E, et al: Cancer
statistics, 2006. CA Cancer J Clin. 56:106–130. 2006. View Article : Google Scholar
|
|
2
|
Kornmann M, Beger HG and Link KH:
Chemosensitivity testing and test-directed chemotherapy in human
pancreatic cancer. Recent Results Cancer Res. 161:180–195. 2003.
View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Papageorgio C and Perry MC: Epidermal
growth factor receptor-targeted therapy for pancreatic cancer.
Cancer Invest. 25:647–657. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Yarden Y: The EGFR family and its ligands
in human cancer. signalling mechanisms and therapeutic
opportunities. Eur J Cancer. 37(Suppl 4): S3–S8. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Kelley RK and Ko AH: Erlotinib in the
treatment of advanced pancreatic cancer. Biologics. 2:83–95.
2008.
|
|
6
|
Moore MJ, Goldstein D, Hamm J, et al:
Erlotinib plus gemcitabine compared with gemcitabine alone in
patients with advanced pancreatic cancer: a phase III trial of the
National Cancer Institute of Canada Clinical Trials Group. J Clin
Oncol. 25:1960–1966. 2007. View Article : Google Scholar
|
|
7
|
Rajput A, Koterba AP, Kreisberg JI, Foster
JM, Willson JK and Brattain MG: A novel mechanism of resistance to
epidermal growth factor receptor antagonism in vivo. Cancer Res.
67:665–673. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Feldmann G, Dhara S, Fendrich V, et al:
Blockade of hedgehog signaling inhibits pancreatic cancer invasion
and metastases: a new paradigm for combination therapy in solid
cancers. Cancer Res. 67:2187–2196. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Hu WG, Wang CY, Liu T, Xiong JX and Yang
ZY: Expression of sonic hedgehog, EGFR and PCNA proteins in
pancreatic cancer and their correlations to cell proliferation. Ai
Zheng. 26:947–951. 2007.(In Chinese).
|
|
10
|
Ciardiello F and Tortora G: EGFR
antagonists in cancer treatment. N Engl J Med. 358:1160–1174. 2008.
View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Berman DM, Karhadkar SS, Hallahan AR, et
al: Medulloblastoma growth inhibition by hedgehog pathway blockade.
Science. 297:1559–1561. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Jorissen RN, Walker F, Pouliot N, Garrett
TP, Ward CW and Burgess AW: Epidermal growth factor receptor:
mechanisms of activation and signalling. Exp Cell Res. 284:31–53.
2003. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Shi F, Telesco SE, Liu Y, Radhakrishnan R
and Lemmon MA: ErbB3/HER3 intracellular domain is competent to bind
ATP and catalyze autophosphorylation. Proc Natl Acad Sci USA.
107:7692–7697. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Larsen AK, Ouaret D, El Ouadrani K and
Petitprez A: Targeting EGFR and VEGF(R) pathway cross-talk in tumor
survival and angiogenesis. Pharmacol Ther. 131:80–90. 2011.
View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Lee CJ, Dosch J and Simeone DM: Pancreatic
cancer stem cells. J Clin Oncol. 26:2806–2812. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Berman DM, Karhadkar SS, Maitra A, et al:
Widespread requirement for Hedgehog ligand stimulation in growth of
digestive tract tumours. Nature. 425:846–851. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Thayer SP, di Magliano MP, Heiser PW, et
al: Hedgehog is an early and late mediator of pancreatic cancer
tumorigenesis. Nature. 425:851–856. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Chen JK, Taipale J, Cooper MK and Beachy
PA: Inhibition of Hedgehog signaling by direct binding of
cyclopamine to Smoothened. Genes Dev. 16:2743–2748. 2002.
View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Buck E, Eyzaguirre A, Haley JD, Gibson NW,
Cagnoni P and Iwata KK: Inactivation of Akt by the epidermal growth
factor receptor inhibitor erlotinib is mediated by HER-3 in
pancreatic and colorectal tumor cell lines and contributes to
erlotinib sensitivity. Mol Cancer Ther. 5:2051–2059. 2006.
View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Dragovich T and Campen C:
Anti-EGFR-targeted therapy for esophageal and gastric cancers: an
evolving concept. J Oncol. 2009:8041082009. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Hu WG, Liu T, Xiong JX and Wang CY:
Blockade of sonic hedgehog signal pathway enhances
antiproliferative effect of EGFR inhibitor in pancreatic cancer
cells. Acta Pharmacol Sin. 28:1224–1230. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Qualtrough D, Buda A, Gaffield W, Williams
AC and Paraskeva C: Hedgehog signalling in colorectal tumour cells:
induction of apoptosis with cyclopamine treatment. Int J Cancer.
110:831–837. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Klapper LN, Kirschbaum MH, Sela M and
Yarden Y: Biochemical and clinical implications of the ErbB/HER
signaling network of growth factor receptors. Adv Cancer Res.
77:25–79. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Tortora G, Bianco R, Daniele G, et al:
Overcoming resistance to molecularly targeted anticancer therapies:
rational drug combinations based on EGFR and MAPK inhibition for
solid tumours and haematologic malignancies. Drug Resist Updat.
10:81–100. 2007. View Article : Google Scholar
|
|
25
|
Faller BA and Burtness B: Treatment of
pancreatic cancer with epidermal growth factor receptor-targeted
therapy. Biologics. 3:419–428. 2009.PubMed/NCBI
|
|
26
|
Jimeno A, Rubio-Viqueira B, Amador ML, et
al: Epidermal growth factor receptor dynamics influences response
to epidermal growth factor receptor targeted agents. Cancer Res.
65:3003–3010. 2005.PubMed/NCBI
|
|
27
|
Hill CS and Treisman R: Transcriptional
regulation by extracellular signals: mechanisms and specificity.
Cell. 80:199–211. 1995. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Bononi A, Agnoletto C, De Marchi E, et al:
Protein kinases and phosphatases in the control of cell fate.
Enzyme Res. 2011:3290982011. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Franke TF, Yang SI, Chan TO, et al: The
protein kinase encoded by the Akt proto-oncogene is a target of the
PDGF-activated phosphatidylinositol 3-kinase. Cell. 81:727–736.
1995. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Scheid MP, Marignani PA and Woodgett JR:
Multiple phosphoinositide 3-kinase-dependent steps in activation of
protein kinase B. Mol Cell Biol. 22:6247–6260. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Sarbassov DD, Guertin DA, Ali SM and
Sabatini DM: Phosphorylation and regulation of Akt/PKB by the
rictor-mTOR complex. Science. 307:1098–1101. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Chappell WH, Steelman LS, Long JM, et al:
Ras/Raf/MEK/ERK and PI3K/PTEN/Akt/mTOR inhibitors: rationale and
importance to inhibiting these pathways in human health.
Oncotarget. 2:135–164. 2011.PubMed/NCBI
|
|
33
|
Datta SR, Dudek H, Tao X, Masters S, Fu H,
Gotoh Y and Greenberg ME: Akt phosphorylation of BAD couples
survival signals to the cell-intrinsic death machinery. Cell.
91:231–241. 1997. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Brunet A, Bonni A, Zigmond MJ, et al: Akt
promotes cell survival by phosphorylating and inhibiting a Forkhead
transcription factor. Cell. 96:857–868. 1999. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Cardone MH, Roy N, Stennicke HR, et al:
Regulation of cell death protease caspase-9 by phosphorylation.
Science. 282:1318–1321. 1998. View Article : Google Scholar : PubMed/NCBI
|
